Last reviewed · How we verify
VG161
At a glance
| Generic name | VG161 |
|---|---|
| Sponsor | Virogin Biotech Canada Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma (PHASE2)
- Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma (PHASE2)
- Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer (PHASE1)
- An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (PHASE2)
- Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma (PHASE1, PHASE2)
- Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer (PHASE1, PHASE2)
- Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VG161 CI brief — competitive landscape report
- VG161 updates RSS · CI watch RSS
- Virogin Biotech Canada Ltd portfolio CI